Table 4 Baseline characteristics of included studies
Author | Country | Year | Design | Mean age (y) | OA, primary (N) | Severe OA Takakura/ KL 3–4 (%) | PRP (N) | Comparator (N) | Male (%) | FU Time (week) | Outcome |
|---|---|---|---|---|---|---|---|---|---|---|---|
Angthong [30] | Thailand | 2013 | Retrospective Before–after descriptive | 50.8 | 5, NA | 20 | 5 | No | 60 | 192 | VAS-FA SF-36 |
Fukawa [12] | Japan | 2017 | Prospective Before–after descriptive | 59.3 | 20, 20 | 10 | 20 | No | 25 | 24 | VAS JSSF SAFE-Q |
Repetto [29] | Italy | 2017 | Retrospective Before–after descriptive | 57.5 | 20, 0 | 100 | 20 | No | 60 | 212 | VAS FADI |
Paget [11] | Netherlands | 2021 | RCT | 55.6 | 100, 1 | 100 | 48 | Placebo (52) | 54 | 26 | VAS AOFAS FAO AOS AAS SF-36 EQ5D3L |
Sun [13] | Taiwan | 2021 | Prospective Before–after descriptive | 55.5 | 39, NA | 28.2 | 39 | No | 43 | 24 | VAS AOFAS AOS |